25 XP   0   0   10

Burzynski Research
Buy, Hold or Sell?

Let's analyse Burzynski Research together

PenkeI guess you are interested in Burzynski Research. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Burzynski Research. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Burzynski Research

I send you an email if I find something interesting about Burzynski Research.

Quick analysis of Burzynski Research (30 sec.)










What can you expect buying and holding a share of Burzynski Research? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$0.00
How sure are you?
52.5%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-0.1%

For what price can you sell your share?

Current Price per Share
$0.04
Expected price per share
$0.043 - $0.052
How sure are you?
50%

1. Valuation of Burzynski Research (5 min.)




Live pricePrice per Share (EOD)

$0.04

Intrinsic Value Per Share

$-0.05 - $-0.04

Total Value Per Share

$-0.05 - $-0.04

2. Growth of Burzynski Research (5 min.)




Is Burzynski Research growing?

Current yearPrevious yearGrowGrow %
How rich?-$34.8k-$19.4k-$11.4k-37.1%

How much money is Burzynski Research making?

Current yearPrevious yearGrowGrow %
Making money-$68k-$217.7k$149.7k220.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Burzynski Research (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#856 / 1004

Most Revenue
#893 / 1004

Most Profit
#169 / 1004

Most Efficient
#309 / 1004

What can you expect buying and holding a share of Burzynski Research? (5 min.)

Welcome investor! Burzynski Research's management wants to use your money to grow the business. In return you get a share of Burzynski Research.

What can you expect buying and holding a share of Burzynski Research?

First you should know what it really means to hold a share of Burzynski Research. And how you can make/lose money.

Speculation

The Price per Share of Burzynski Research is $0.044. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Burzynski Research.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Burzynski Research, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Burzynski Research.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-7.5%0.00-5.4%0.00-3.8%0.00-5.3%0.00-7.0%
Usd Book Value Change Per Share0.00-0.5%0.000.0%0.00-0.1%0.000.1%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.5%0.000.0%0.00-0.1%0.000.1%0.000.1%
Usd Price Per Share0.04-0.05-0.02-0.03-0.05-
Price to Earnings Ratio-3.19--5.13--3.74--3.66--4.16-
Price-to-Total Gains Ratio-181.86-37.95--277.29--43.72-1,487.94-
Price to Book Ratio-158.49--508.57-714.40-44.41--25.28-
Price-to-Total Gains Ratio-181.86-37.95--277.29--43.72-1,487.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.044
Number of shares22727
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (22727 shares)-0.351.19
Gains per Year (22727 shares)-1.424.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1-1105-5
20-3-12090
30-4-130145
40-6-1401910
50-7-1502415
60-9-1602820
70-10-1703325
80-11-1803830
90-13-1904335
100-14-2004740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.095.00.00.0%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%10.010.00.050.0%21.018.01.052.5%42.048.05.044.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.095.00.0%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%10.010.00.050.0%21.018.01.052.5%42.048.05.044.2%

Fundamentals of Burzynski Research

About Burzynski Research

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to the treatment of various cancers. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was incorporated in 1984 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2024-05-15 02:02:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Burzynski Research.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Burzynski Research earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Burzynski Research:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--176.9%+176.9%
TTM--211.5%+211.5%
YOY--266.0%+266.0%
5Y--401.1%+401.1%
10Y--552.5%+552.5%
1.1.2. Return on Assets

Shows how efficient Burzynski Research is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • -42,745.8% Return on Assets means that Burzynski Research generated $-427.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Burzynski Research:

  • The MRQ is -42,745.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13,614.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-42,745.8%TTM-13,614.4%-29,131.4%
TTM-13,614.4%YOY-8,741.0%-4,873.3%
TTM-13,614.4%5Y-8,731.2%-4,883.2%
5Y-8,731.2%10Y-17,676.3%+8,945.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42,745.8%-12.1%-42,733.7%
TTM-13,614.4%-11.7%-13,602.7%
YOY-8,741.0%-11.0%-8,730.0%
5Y-8,731.2%-13.2%-8,718.0%
10Y-17,676.3%-14.5%-17,661.8%
1.1.3. Return on Equity

Shows how efficient Burzynski Research is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • 0.0% Return on Equity means Burzynski Research generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Burzynski Research:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3,542.3%+3,542.3%
TTM-5Y-955.9%+955.9%
5Y-955.9%10Y-478.0%-478.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.4%+15.4%
TTM--15.0%+15.0%
YOY-3,542.3%-13.7%-3,528.6%
5Y-955.9%-17.8%-938.1%
10Y-478.0%-19.3%-458.7%

1.2. Operating Efficiency of Burzynski Research.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Burzynski Research is operating .

  • Measures how much profit Burzynski Research makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Burzynski Research:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--339.4%+339.4%
TTM--221.5%+221.5%
YOY--281.8%+281.8%
5Y--408.0%+408.0%
10Y--528.5%+528.5%
1.2.2. Operating Ratio

Measures how efficient Burzynski Research is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Burzynski Research:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.076-3.076
TTM-3.246-3.246
YOY-3.609-3.609
5Y-5.190-5.190
10Y-6.896-6.896

1.3. Liquidity of Burzynski Research.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Burzynski Research is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.03 means the company has $0.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Burzynski Research:

  • The MRQ is 0.028. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.113. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.028TTM0.113-0.084
TTM0.113YOY0.411-0.299
TTM0.1135Y0.388-0.276
5Y0.38810Y0.228+0.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0283.802-3.774
TTM0.1134.158-4.045
YOY0.4115.249-4.838
5Y0.3886.087-5.699
10Y0.2286.428-6.200
1.3.2. Quick Ratio

Measures if Burzynski Research is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • A Quick Ratio of 0.03 means the company can pay off $0.03 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Burzynski Research:

  • The MRQ is 0.025. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.077. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.025TTM0.077-0.052
TTM0.077YOY0.307-0.230
TTM0.0775Y0.289-0.211
5Y0.28910Y0.150+0.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0253.246-3.221
TTM0.0773.811-3.734
YOY0.3075.150-4.843
5Y0.2895.929-5.640
10Y0.1506.351-6.201

1.4. Solvency of Burzynski Research.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Burzynski Research assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Burzynski Research to Biotechnology industry mean.
  • A Debt to Asset Ratio of 35.39 means that Burzynski Research assets are financed with 3,538.7% credit (debt) and the remaining percentage (100% - 3,538.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Burzynski Research:

  • The MRQ is 35.387. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 32.783. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ35.387TTM32.783+2.604
TTM32.783YOY8.466+24.318
TTM32.7835Y23.280+9.503
5Y23.28010Y42.516-19.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ35.3870.351+35.036
TTM32.7830.343+32.440
YOY8.4660.278+8.188
5Y23.2800.366+22.914
10Y42.5160.379+42.137
1.4.2. Debt to Equity Ratio

Measures if Burzynski Research is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Burzynski Research to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Burzynski Research:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.716-0.716
TTM-5Y0.156-0.156
5Y0.15610Y0.078+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.402-0.402
TTM-0.415-0.415
YOY0.7160.351+0.365
5Y0.1560.442-0.286
10Y0.0780.469-0.391

2. Market Valuation of Burzynski Research

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Burzynski Research generates.

  • Above 15 is considered overpriced but always compare Burzynski Research to the Biotechnology industry mean.
  • A PE ratio of -3.19 means the investor is paying $-3.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Burzynski Research:

  • The EOD is -3.339. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.187. Based on the earnings, the company is expensive. -2
  • The TTM is -5.134. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.339MRQ-3.187-0.152
MRQ-3.187TTM-5.134+1.946
TTM-5.134YOY-3.744-1.390
TTM-5.1345Y-3.655-1.479
5Y-3.65510Y-4.161+0.506
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.339-2.413-0.926
MRQ-3.187-2.573-0.614
TTM-5.134-2.766-2.368
YOY-3.744-3.948+0.204
5Y-3.655-6.374+2.719
10Y-4.161-6.660+2.499
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Burzynski Research:

  • The EOD is -7.191. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.864. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -16.705. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.191MRQ-6.864-0.327
MRQ-6.864TTM-16.705+9.842
TTM-16.705YOY-14.076-2.629
TTM-16.7055Y-11.564-5.141
5Y-11.56410Y-21.340+9.776
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.191-3.085-4.106
MRQ-6.864-3.312-3.552
TTM-16.705-3.529-13.176
YOY-14.076-5.200-8.876
5Y-11.564-8.251-3.313
10Y-21.340-8.842-12.498
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Burzynski Research is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -158.49 means the investor is paying $-158.49 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Burzynski Research:

  • The EOD is -166.037. Based on the equity, the company is expensive. -2
  • The MRQ is -158.490. Based on the equity, the company is expensive. -2
  • The TTM is -508.569. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-166.037MRQ-158.490-7.547
MRQ-158.490TTM-508.569+350.079
TTM-508.569YOY714.398-1,222.967
TTM-508.5695Y44.414-552.983
5Y44.41410Y-25.276+69.690
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-166.0372.082-168.119
MRQ-158.4902.031-160.521
TTM-508.5692.076-510.645
YOY714.3982.688+711.710
5Y44.4143.692+40.722
10Y-25.2764.104-29.380
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Burzynski Research compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0000.000-93%0.000-74%0.000-543%0.000-870%
Book Value Per Share--0.0000.000-11%0.000-44%-0.001+160%-0.001+202%
Current Ratio--0.0280.113-75%0.411-93%0.388-93%0.228-88%
Debt To Asset Ratio--35.38732.783+8%8.466+318%23.280+52%42.516-17%
Debt To Equity Ratio----0%0.716-100%0.156-100%0.078-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.003-0.002-27%-0.002-50%-0.002-29%-0.003-6%
Free Cash Flow Per Share---0.002-0.001-43%0.000-71%-0.001-50%-0.001-54%
Free Cash Flow To Equity Per Share--0.0000.000-60%0.000+110%0.000-2367%0.000-423%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.037--------
Intrinsic Value_10Y_min---0.049--------
Intrinsic Value_1Y_max---0.003--------
Intrinsic Value_1Y_min---0.003--------
Intrinsic Value_3Y_max---0.009--------
Intrinsic Value_3Y_min---0.011--------
Intrinsic Value_5Y_max---0.016--------
Intrinsic Value_5Y_min---0.021--------
Market Cap5783712.000+5%5520834.6486145214.757-10%3121900.545+77%4003919.604+38%6778796.257-19%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-166.037-5%-158.490-508.569+221%714.398-122%44.414-457%-25.276-84%
Pe Ratio-3.339-5%-3.187-5.134+61%-3.744+17%-3.655+15%-4.161+31%
Price Per Share0.044+5%0.0420.047-10%0.024+77%0.030+38%0.052-19%
Price To Free Cash Flow Ratio-7.191-5%-6.864-16.705+143%-14.076+105%-11.564+68%-21.340+211%
Price To Total Gains Ratio-190.518-5%-181.85837.949-579%-277.286+52%-43.719-76%1487.940-112%
Quick Ratio--0.0250.077-67%0.307-92%0.289-91%0.150-83%
Return On Assets---427.458-136.144-68%-87.410-80%-87.312-80%-176.763-59%
Return On Equity----0%-35.4230%-9.5590%-4.7800%
Total Gains Per Share--0.0000.000-93%0.000-74%0.000-543%0.000-870%
Usd Book Value---34834.000-30888.750-11%-19435.000-44%-90582.050+160%-105142.500+202%
Usd Book Value Change Per Share--0.0000.000-93%0.000-74%0.000-543%0.000-870%
Usd Book Value Per Share--0.0000.000-11%0.000-44%-0.001+160%-0.001+202%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.003-0.002-27%-0.002-50%-0.002-29%-0.003-6%
Usd Free Cash Flow---201089.000-114858.750-43%-58585.500-71%-99557.550-50%-92880.900-54%
Usd Free Cash Flow Per Share---0.002-0.001-43%0.000-71%-0.001-50%-0.001-54%
Usd Free Cash Flow To Equity Per Share--0.0000.000-60%0.000+110%0.000-2367%0.000-423%
Usd Market Cap5783712.000+5%5520834.6486145214.757-10%3121900.545+77%4003919.604+38%6778796.257-19%
Usd Price Per Share0.044+5%0.0420.047-10%0.024+77%0.030+38%0.052-19%
Usd Profit---433015.000-68057.500-84%-217793.250-50%-256324.550-41%-382620.800-12%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.0000.000-93%0.000-74%0.000-543%0.000-870%
 EOD+6 -2MRQTTM+1 -26YOY+8 -205Y+8 -2010Y+7 -21

3.2. Fundamental Score

Let's check the fundamental score of Burzynski Research based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.339
Price to Book Ratio (EOD)Between0-1-166.037
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.025
Current Ratio (MRQ)Greater than10.028
Debt to Asset Ratio (MRQ)Less than135.387
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-427.458
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Burzynski Research based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.343
Ma 20Greater thanMa 500.042
Ma 50Greater thanMa 1000.033
Ma 100Greater thanMa 2000.034
OpenGreater thanClose0.044
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-11-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1
Total Liabilities36
Total Stockholder Equity-35
 As reported
Total Liabilities 36
Total Stockholder Equity+ -35
Total Assets = 1

Assets

Total Assets1
Total Current Assets1
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 1
Other Current Assets 0
Total Current Assets  (as reported)1
Total Current Assets  (calculated)1
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36
Long-term Liabilities0
Total Stockholder Equity-35
Total Current Liabilities
Accounts payable 20
Other Current Liabilities 16
Total Current Liabilities  (as reported)36
Total Current Liabilities  (calculated)36
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock131
Retained Earnings -127,727
Other Stockholders Equity 127,561
Total Stockholder Equity (as reported)-35
Total Stockholder Equity (calculated)-35
+/-0
Other
Capital Stock131
Cash and Short Term Investments 1
Common Stock Shares Outstanding 131,448
Liabilities and Stockholders Equity 1
Net Debt -1
Net Invested Capital -35
Net Working Capital -35



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-282008-11-302008-08-312008-05-312008-02-292007-11-302007-08-312007-05-312007-02-282006-11-302006-08-312006-05-312006-02-282005-11-302005-08-312005-05-312005-02-282004-11-302004-08-312004-05-312004-02-292003-11-302003-08-312003-05-312003-02-282002-11-302002-08-312002-05-312002-02-282001-11-302001-08-312001-05-312001-02-282000-02-291999-11-301999-08-311999-05-31
> Total Assets 
0
0
0
195
195
108
98
78
92
69
69
87
66
86
82
65
74
74
77
78
66
61
57
95
21
20
19
19
13
31
13
9
10
11
19
15
16
21
19
20
23
23
21
21
22
20
26
20
21
18
17
6
4
4
3
2
2
4
8
4
4
2
2
1
4
4
1
1
11
0
1
36
29
17
45
34
22
13
46
33
20
9
3
2
1
2
2
7
5
5
2
2
2
1
2
1
1212225572212392033461322344517293610111144122448422344617182120262022212123232019211615191110913311319192021955761667877747465828666876969927898108195195000
   > Total Current Assets 
0
0
0
20
20
12
13
4
23
4
8
19
2
26
23
11
20
20
25
27
17
14
11
91
18
17
16
17
11
22
5
1
3
4
12
9
11
16
13
15
18
18
16
17
17
16
22
16
17
15
14
3
1
1
1
0
0
2
6
2
2
0
1
1
3
3
0
1
11
0
1
36
29
17
45
34
22
13
46
33
20
9
3
2
1
2
2
7
5
5
2
2
2
1
2
1
12122255722123920334613223445172936101110331102262001113141517162216171716181815131611912431522111716171891111417272520201123262198423413122020000
       Cash And Cash Equivalents 
0
0
0
20
20
12
13
4
23
4
8
19
2
25
23
11
19
19
25
27
17
14
11
11
18
17
16
17
11
22
5
1
3
4
12
9
11
16
13
15
18
18
16
17
17
16
22
16
17
15
14
3
1
1
1
0
0
2
6
2
2
0
1
1
3
3
0
1
1
0
1
3
1
0
0
0
1
3
1
0
0
0
2
1
0
1
1
6
3
5
1
2
1
0
1
1
110121536110120001310001310110331102262001113141517162216171716181815131611912431522111716171811111417272519191123252198423413122020000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000008000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
0
33
28
17
45
33
21
10
45
32
20
9
1
1
1
1
1
1
1
1
0
0
1
1
0
0
001100111111119203245102133451728330101000000000000000000000000000000000000000000000000000110010000000000000
   > Long-term Assets 
0
0
0
174
174
96
84
75
69
65
60
68
64
60
59
54
54
54
52
50
49
48
46
4
4
3
3
3
2
9
8
8
7
7
6
6
6
6
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000001111112222223333334444445555666677889233344464849505254545459606468606569758496174174000
       Property Plant Equipment 
0
0
0
170
170
96
84
75
69
65
60
68
64
60
59
54
54
54
52
50
49
48
46
4
4
3
3
3
2
9
8
8
7
7
6
6
6
6
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000001111112222223333334444445555666677889233344464849505254545459606468606569758496170170000
> Total Liabilities 
0
0
0
209
209
112
43
28
58
74
54
87
70
109
84
110
107
107
132
103
87
86
65
50
50
72
58
41
66
96
89
86
69
81
88
57
104
129
203
113
71
71
127
49
73
92
37
48
62
136
46
90
89
137
179
195
153
134
137
115
142
132
135
128
105
105
110
73
44
89
129
163
137
153
213
206
209
213
229
216
172
255
204
131
47
63
30
1
3
44
15
28
16
71
6
36
3667116281544313063471312042551722162292132092062131531371631298944731101051051281351321421151371341531951791378990461366248379273491277171113203129104578881698689966641587250506586871031321071071108410970875474582843112209209000
   > Total Current Liabilities 
0
0
0
209
209
112
43
28
58
74
54
87
70
109
84
110
107
107
132
103
87
86
65
50
50
72
58
41
66
96
89
86
69
81
88
57
104
129
203
113
71
71
127
49
73
92
37
48
62
136
46
90
89
137
179
195
153
134
137
115
142
132
135
128
105
105
110
73
44
89
129
163
137
153
213
206
209
213
229
216
172
255
204
131
47
63
30
1
3
44
15
28
16
71
6
36
3667116281544313063471312042551722162292132092062131531371631298944731101051051281351321421151371341531951791378990461366248379273491277171113203129104578881698689966641587250506586871031321071071108410970875474582843112209209000
       Short-term Debt 
0
0
0
5
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000235000
       Accounts payable 
0
0
0
48
48
57
12
1
11
46
21
32
23
46
25
66
56
56
86
59
47
45
28
14
14
37
23
19
44
48
47
49
33
53
74
40
78
103
178
88
42
42
97
19
39
26
3
4
12
55
11
53
48
40
153
163
114
108
113
91
100
82
93
87
64
64
79
49
20
60
61
68
42
65
96
98
101
97
93
94
61
142
86
22
33
30
19
1
0
14
2
17
13
23
0
20
200231317214011930332286142619493971019896654268616020497964648793821009111310811416315340485311551243263919974242881781037840745333494748441923371414284547598656566625462332214611112574848000
       Other Current Liabilities 
0
0
0
155
138
54
30
26
46
28
32
55
47
63
59
44
51
51
47
43
39
41
37
36
36
35
35
21
22
48
42
37
35
28
14
17
25
26
25
26
30
30
30
30
34
66
33
44
50
81
35
37
41
97
26
32
39
26
24
24
42
51
42
40
41
41
31
24
24
29
68
95
95
88
117
107
108
116
136
122
112
113
118
110
14
33
10
0
3
30
13
12
3
49
6
16
16649312133030103314110118113112122136116108107117889595682924243141414042514224242639322697413735815044336634303030302625262517142835374248222135353636374139434751514459634755322846263054138155000
   > Long-term Liabilities 
0
0
0
0
0
57
12
1
11
46
21
32
23
46
25
66
0
56
86
59
47
45
28
14
14
37
23
19
44
48
47
49
33
53
74
40
78
103
178
88
0
42
97
19
39
26
3
4
12
55
11
53
48
40
153
163
114
108
113
91
100
82
93
87
0
64
79
49
20
60
61
68
42
65
96
98
101
97
93
94
61
142
86
22
33
30
19
1
0
14
2
17
13
0
0
0
00013172140119303322861426194939710198966542686160204979640879382100911131081141631534048531155124326391997420881781037840745333494748441923371414284547598656066254623322146111125700000
> Total Stockholder Equity
0
0
0
-14
-14
-3
55
51
34
-5
15
0
-5
-23
-2
-45
-33
-33
-56
-25
-21
-24
-8
45
-28
-52
-39
-21
-53
-65
-76
-77
-58
-70
-70
-43
-87
-108
-184
-93
-48
-48
-106
-27
-51
-72
-10
-28
-41
-118
-28
-85
-85
-133
-176
-193
-151
-130
-130
-111
-138
-131
-133
-126
-101
-101
-109
-72
-33
-89
-128
-127
-108
-137
-167
-172
-187
-200
-182
-183
-153
-245
-201
-129
-46
-61
-28
5
1
-39
-14
-27
-14
-71
-4
-35
-35-4-71-14-27-14-3915-28-61-46-129-201-245-153-183-182-200-187-172-167-137-108-127-128-89-33-72-109-101-101-126-133-131-138-111-130-130-151-193-176-133-85-85-28-118-41-28-10-72-51-27-106-48-48-93-184-108-87-43-70-70-58-77-76-65-53-21-39-52-2845-8-24-21-25-56-33-33-45-2-23-5015-5345155-3-14-14000
   Common Stock
0
0
0
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131
131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131131000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000-22-220-22-22-22-21-21-210-210-200-20-20-20-20-19-19-19-19-19-18-18-18-18-18-18-17-17-17-17000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
42,344
42,344
48,363
49,739
50,954
52,161
53,199
54,235
55,328
56,543
57,589
58,751
59,596
60,899
60,899
63,381
64,572
65,876
67,056
68,380
69,472
70,469
71,603
72,763
73,739
74,747
75,796
76,939
77,967
79,264
80,535
820,062
83,195
84,363
85,462
86,580
87,879
89,250
89,232
91,755
93,043
94,261
95,741
97,588
99,410
101,428
103,032
104,916
106,389
107,884
109,192
110,256
111,222
112,090
112,951
113,678
114,404
114,994
115,626
116,134
116,601
117,058
117,036
117,800
118,221
118,609
119,014
119,401
119,803
120,146
120,527
120,946
121,381
121,705
122,160
122,588
123,059
123,374
123,739
124,112
124,448
124,685
124,985
125,244
125,542
125,708
125,900
126,141
126,381
126,610
126,840
127,158
127,561
127,561127,158126,840126,610126,381126,141125,900125,708125,542125,244124,985124,685124,448124,112123,739123,374123,059122,588122,160121,705121,381120,946120,527120,146119,803119,401119,014118,609118,221117,800117,036117,058116,601116,134115,626114,994114,404113,678112,951112,090111,222110,256109,192107,884106,389104,916103,032101,42899,41097,58895,74194,26193,04391,75589,23289,25087,87986,58085,46284,36383,195820,06280,53579,26477,96776,93975,79674,74773,73972,76371,60370,46969,47268,38067,05665,87664,57263,38160,89960,89959,59658,75157,58956,54355,32854,23553,19952,16150,95449,73948,36342,34442,344000



Balance Sheet

Currency in USD. All numbers in thousands.